Liquid Biopsy Market - Strategic Insights and Forecasts (2026-2031)

Liquid Biopsy Market is set to grow at a CAGR of 16.40%, moving from USD 8.2 billion in 2026 to USD 17.5 billion by 2031.

Liquid biopsy methods measure tumour-derived signals (ctDNA, cfDNA, CTCs, EVs) in biological fluids. Over the past three years vendors and service providers shifted from early-stage research tools to clinically validated assays and screening products; the result is stronger pull from clinical oncology programs, payer determinations, and centralized laboratory networks. The remainder of this report analyzes demand drivers, constraints, supply chain realities, regulatory impact, segment-level demand, country-level demand drivers, competitive positioning, and verified 2024–2025 company developments.

Liquid Biopsy Market Analysis:

• Growth Drivers

Clinical utility evidence and payer actions drove immediate demand in 2024. FDA guidance on use of ctDNA for early-stage drug development and regulatory acceptances of companion/compendia tests created clear pathways for clinical adoption, increasing clinical-testing volumes and demand for validated assays and high-sensitivity platforms. Commercial screening approvals and Medicare pricing decisions (for Guardant Shield and similar programs) converted clinical interest into reimbursable activity, directly increasing ordering from oncologists and screening programs. Concurrently, technology upgrades (digital PCR/NGS instrument launches and pre-analytical kits) reduced per-sample labor and error, enabling larger centralized throughput and proportionally greater demand for consumables and lab services.

• Challenges and Opportunities

U.S. demand for liquid biopsy products is shaped in part by the tariff treatment of diagnostic reagents, nucleic-acid extraction kits, and sequencing consumables imported for clinical and research use. Most liquid biopsy components enter the United States under HTS categories covering in-vitro diagnostic reagents, laboratory instruments, and plastic consumables, which historically carry low or zero MFN tariff rates, according to publicly available U.S. International Trade Commission (USITC) tariff schedules. Because these inputs are essential for high-complexity lab operations, low tariff burdens help preserve cost stability for U.S. laboratories and maintain steady demand for imported extraction chemistries, collection tubes, assay kits, and sequencing consumables. However, products originating from countries subject to Section 301 trade measures—particularly certain molecular biology reagents manufactured in China—may face additional duties. These elevated duties increase procurement costs for some laboratories, creating incentives for U.S. buyers to shift to domestic or non-Chinese suppliers or to increase bulk purchasing to offset price volatility.

Headwinds stem from stricter regulatory evidence expectations (IVDR and FDA guidance) that increase time and cost to market for new assays, suppressing supply of unvalidated tests and raising barriers for smaller vendors. Reimbursement variability across jurisdictions creates uneven demand—favourable US Medicare decisions spur rapid uptake, whereas slow or absent coverage in other markets delays adoption. Opportunities arise where payers and national health services adopt ctDNA testing (screening, minimal residual disease monitoring): validated, reimbursed assays drive recurring demand for sequencing, analysis software, and centralized lab capacity. Pre-analytic standardization (urine cfDNA kits, automated extraction) opens non-blood sample markets and expands addressable patient populations.

• Raw Material and Pricing Analysis

Liquid biopsy is productized through reagents, kits, sequencing consumables, and instruments. Key raw inputs are nucleic-acid extraction chemistries, library-preparation reagents, and NGS flow-cells or digital-PCR consumables. Pricing dynamics reflect concentration: a small number of instrument/platform suppliers (NGS and dPCR) control large portions of consumable demand; instrument refresh cycles and capacity expansions push orders for cartridges and reagents. Supply constraints for high-quality enzymes or specialized oligos can cause short-term price pressure on assay manufacturers. Vendors responded in 2024–2025 by bundling validated reagent kits with instruments and by offering higher-margin clinical-grade kits to stabilize per-test economics.

• Supply Chain Analysis

Production hubs are concentrated in Europe, North America, and parts of Asia where instrument manufacturing, reagent production, and high-complexity labs co-locate. Logistical complexities include cold-chain transport for stabilized blood/urine collection kits, single-site laboratory workflows for certain FDA-approved assays, and cross-border regulatory documentation for IVD imports. Dependencies include a small set of specialized component suppliers (enzymes, oligonucleotides) and a limited number of accredited sequencing instrument manufacturers; disruptions in any node cause lead-time increases that directly reduce laboratory throughput and demand. Companies mitigated risk in 2024 with localized kit production and formal distribution agreements for critical consumables.

• Government Regulations

Liquid Biopsy Market Segment Analysis

• Screening (By Application)

Screening converts liquid biopsy from episodic clinical use into high-volume, recurring demand. In 2024 Guardant’s screening product activity and related payer actions illustrated the mechanics: when a screening assay achieves regulatory acceptance and reimbursement, ordering shifts from pilot programs to population-level initiatives, creating steady per-patient consumable demand, centralized sequencing capacity needs, and demand for validated pre-analytical kits. Screening requires high negative predictive value, standardized collection, and robust quality-control; therefore payers and public health authorities preferentially adopt assays with prospective validation and clear clinical pathways. The result is demand concentration on vendors that supply validated end-to-end workflows (collection, stabilization, extraction, analysis) and labs that can scale. Screening also increases demand for interpretation solutions and reporting workflows, since large screenings generate high volumes of actionable variants and require standardized clinical reporting and follow-up referral pathways. Screening adoption in one jurisdiction often causes regional spillover demand as other payers benchmark outcomes.

• Circulating Tumor DNA (ctDNA — By Biomarker/Technology)

ctDNA is the primary commercial driver of liquid biopsy demand because it directly supports companion diagnostics, minimal residual disease (MRD) monitoring, drug response assessment, and screening. Regulatory agencies produced guidance and approvals specifically referencing ctDNA, which raises bar for analytical sensitivity and clinical validation but also formalizes commercialization pathways. High-sensitivity ctDNA assays require low input-mass extraction chemistries, deep-coverage sequencing, or highly sensitive dPCR; thus demand flows to platforms capable of reliably detecting low-frequency variants and to consumables that maintain analytic performance. Clinical adoption of ctDNA for MRD and therapy selection creates recurring test volumes (surveillance schedules), increasing predictable demand for sequencing runs, bioinformatics pipelines, and interpretation services. Additionally, ctDNA’s utility across multiple tumour types expands the addressable market per patient episode and pulls demand toward multi-gene panels and cloud-enabled reporting solutions.

Liquid Biopsy Market Geographical Analysis

• US Market Analysis

US demand expanded rapidly after FDA guidance and Medicare pricing clarity in 2024; payer decisions translated into higher clinical ordering and centralized lab volumes.

• Brazil Market Analysis (South America)

ANVISA regulatory and clinical evaluation requirements push vendors to localize registration and clinical evidence; adoption follows public and private payer assessments.

• Germany Market Analysis (Europe)

IVDR enforcement increased demand for IVDR-compliant assays and certified labs; manufacturers with EU technical documentation saw prioritized procurement.

• South Africa Market Analysis (Middle East & Africa)

SAHPRA’s developing IVD frameworks emphasize registration and classification; hospitals and private labs drive early demand for validated tests and reference lab services.

• Japan Market Analysis (Asia-Pacific)

PMDA consultation pathways and strong hospital adoption of precision oncology increase demand for cleared assays and localized lab services.

Liquid Biopsy Market Competitive Environment and Analysis

• Major companies (from TOC): F. Hoffmann-La Roche (Foundation Medicine), Guardant Health, Qiagen, Illumina, Bio-Rad, NeoGenomics, Biocept, LungLife AI, Cardiff Oncology, Genomic Health (profiled companies).

Liquid Biopsy Market Company profiles

• Guardant Health — strategic profile

Guardant focused on clinical-grade ctDNA assays and screening products (Guardant Shield); 2024 press releases documented commercial availability and favourable Medicare pricing actions and sequential revenue growth, indicating scaling clinical volumes and increased demand for Guardant360 and Shield testing services.

• QIAGEN — strategic profile

QIAGEN expanded automated liquid biopsy workflows and launched clinical dPCR platforms (QIAcuityDx) and urine cfDNA collection solutions via PreAnalytiX (joint venture). Those product launches directly increased demand for pre-analytic kits and clinical dPCR reagents in late-2024.

• F. Hoffmann-La Roche / Foundation Medicine — strategic profile

Roche’s FoundationOne Liquid CDx is an FDA-approved pan-tumour CGP liquid biopsy, Roche’s Diagnostics communications and Foundation approvals position Roche as a key supplier for companion diagnostics and centralized assay demand.

Liquid Biopsy Market Developments 

• Nov 2024 — Guardant Health reported Q3 2024 results and noted Shield received favorable Medicare pricing; company reported strong clinical volume growth (press releases, Nov 6, 2024 & related investor releases).

• Oct–Sept 2024 — QIAGEN launched the QIAcuityDx digital PCR system for clinical oncology and PreAnalytiX (QIAGEN+BD JV) launched the PAXgene Urine Liquid Biopsy Set (Sept 25, 2024), expanding non-blood sampling workflows.

Liquid Biopsy Market Scope:

Liquid Biopsy Market Segmentation:

• By Sample Tissue

  • Blood

  • Urine

  • Saliva    

  • Others

• By Biomarkers

  • Circulating Tumor Cells (CTCs)

  • Circulating Tumor DNA (ctDNA)

  • Cell-Free DNA (cfDNA)

  • Extracellular Vesicles (EVs)

  • Others

• By Application 

  • Screening

  • Disease Prognosis

  • Drug Response and Resistance

• By Geography

  • North America

    • USA

    • Canada

    • Mexico

  • South America

    • Brazil

    • Argentina

    • Others

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Others

  • Middle East and Africa

    • Saudi Arabia

    • UAE

    • South Africa

    • Others

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Indonesia

    • Taiwan

    • Thailand

    • Others